Rate and Predictors of Unforeseen PN1/PN2-Disease in Surgically Treated cN0 NSCLC-Patients with Primary Tumor > 3 cm: Nationwide Results from Italian VATS-Group Database

Background. Since no robust data are available on the real rate of unforeseen N1-N2 disease (uN) and the relative predictive factors in clinical-N0 NSCLC with peripheral tumours > 3 cm, the usefulness of performing a (mini)invasive mediastinal staging in this setting is debated. Herein, we investigated these issues in a nationwide database. Methods. From 01/2014 to 06/2020, 15,784 thoracoscopic major lung resections were prospectively recorded in the “Italian VATS-Group” database. Among them, 1982 clinical-N0 peripheral solid-type NSCLC > 3 cm were identified, and information was retrospectively reviewed. A mean comparison of more than two groups was made by ANOVA (Bonferroni correction for multiple comparisons), while associations between the categorical variables were estimated with a Chi-square test. The multivariate logistic regression model and Kaplan–Meyer method were used to identify the independent predictors of nodal upstaging and survival results, respectively. Results. At pathological staging, 229 patients had N1-involvement (11.6%), and 169 had uN2 disease (8.5%). Independent predictors of uN1 were SUVmax (OR: 1.98; CI 95: 1.44–2.73, p = 0.0001) and tumour-size (OR: 1.52; CI: 1.11–2.10, p = 0.01), while independent predictors of uN2 were age (OR: 0.98; CI 95: 0.96–0.99, p = 0.039), histology (OR: 0.48; CI 95: 0.30–0.78, p = 0.003), SUVmax (OR: 2.07; CI 95: 1.15–3.72, p = 0.015), and the number of resected lymph nodes (OR: 1.03; CI 95: 1.01–1.05, p = 0.002). Conclusions. The unforeseen N1-N2 disease in cN0/NSCLCs > 3 cm undergoing VATS resection is observable in between 12 and 8% of all cases. We have identified predictors that could guide physicians in selecting the best candidate for (mini)invasive mediastinal staging.

[1]  E. Karapanagiotou,et al.  Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study , 2022, Cancers.

[2]  Marcelo Sánchez,et al.  Is invasive mediastinal staging necessary in intermediate risk patients with negative PET/CT? , 2020, Journal of thoracic disease.

[3]  F. Mucilli,et al.  Mediastinal Up-Staging During Surgery in Non-Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter Analysis. , 2020, Clinical lung cancer.

[4]  F. Rea,et al.  Predictors of nodal upstaging in patients with cT1-3N0 non-small cell lung cancer (NSCLC): results from the Italian VATS Group Registry , 2019, Surgery Today.

[5]  S. Margaritora,et al.  Upstaging, centrality and survival in early stage non-small cell lung cancer video-assisted surgery: Lymph nodal upstaging in lung cancer surgery: is it really a surgical technique problem? , 2019, Lung cancer.

[6]  D. Nachira,et al.  Lymph node upstaging for non-small cell lung cancer after uniportal video-assisted thoracoscopy. , 2018, Journal of thoracic disease.

[7]  Ramón Rami-Porta,et al.  Lung cancer staging: a concise update , 2018, European Respiratory Journal.

[8]  Kyounbun Lee,et al.  Consolidation/Tumor Ratio on Chest Computed Tomography as Predictor of Postoperative Nodal Upstaging in Clinical T1N0 Lung Cancer , 2018, World Journal of Surgery.

[9]  F. Rea,et al.  Predictors of unexpected nodal upstaging in patients with cT1-3N0 non-small cell lung cancer (NSCLC) submitted to thoracoscopic lobectomy. , 2018, Journal of visualized surgery.

[10]  R. Crisci,et al.  Nodal management and upstaging of disease: initial results from the Italian VATS Lobectomy Registry. , 2017, Journal of thoracic disease.

[11]  A. Toker,et al.  Nodal upstaging: effects of instrumentation and three-dimensional view in clinical stage I lung cancer. , 2017, Journal of visualized surgery.

[12]  E. Garelli,et al.  Microscopic N2 disease exhibits a better prognosis in resected non-small-cell lung cancer. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[13]  Hisao Asamura,et al.  The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  C. Dooms,et al.  Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[15]  M. Serra-Mitjans,et al.  Survival of patients with unsuspected pN2 non-small cell lung cancer after an accurate preoperative mediastinal staging. , 2014, The Annals of thoracic surgery.

[16]  P. Licht,et al.  A national study of nodal upstaging after thoracoscopic versus open lobectomy for clinical stage I lung cancer. , 2013, The Annals of thoracic surgery.

[17]  L. Tanoue,et al.  Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[18]  R. Cerfolio,et al.  Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. , 2008, The Annals of thoracic surgery.

[19]  N. Altorki,et al.  Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. , 2007, The Annals of thoracic surgery.

[20]  P. V. Van Schil,et al.  ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[21]  G. Montana,et al.  Association between lower lobe location and upstaging for early-stage non-small cell lung cancer. , 2004, Chest.

[22]  D. Mccrory,et al.  Evidence-Based Clinical Practice Guidelines Medical Therapy For Pulmonary Arterial Hypertension : ACCP , 2004 .